Obesity biotech Kalohexis confidentially files to go public in US

• Kalohexis's lead program, 710GO, is an oral dual MC3/MC4 receptor agonist designed to induce durable weight loss for general obesity treatment
• The company is also developing mifomelatide, a drug aimed at treating cachexia, a life-threatening wasting syndrome in advanced cancer patients
• The company launched after spinning out of Endevica Bio in March, with Endevica Bio's leadership team leading the new venture

Summary

Key Development: Kalohexis, a clinical-stage obesity-focused biotechnology company, confidentially filed for a U.S. initial public offering on July 7, contributing to a recent rebound in IPO market activity. Offering terms have not yet been disclosed.

Company Background: Kalohexis spun out from Endevica Bio in March 2024, retaining the parent company's leadership team. The biotech specializes in treating metabolic disorders by targeting the melanocortin (MC) system, which naturally regulates metabolic homeostasis.

Pipeline Programs:

• 710GO (Lead Program): An oral dual MC3/MC4 receptor agonist designed to produce durable weight loss for general obesity treatment
• Mifomelatide: A dual MC3R/MC4R antagonist aimed at treating cachexia, a life-threatening wasting syndrome in advanced cancer patients

Technology Approach: The company develops proprietary peptides engineered to safely target central regulatory receptors involved in metabolism.

Market Context: This filing adds to growing momentum in the biotech IPO space, particularly within the obesity treatment sector, which has seen significant investor interest amid the success of weight-loss drugs. The confidential filing allows the company to begin the public offering process while keeping financial details private until closer to the actual IPO date.

Implications: Kalohexis enters a competitive but lucrative obesity drug market. Its oral delivery mechanism for 710GO could offer advantages over injectable competitors, while mifomelatide addresses an underserved medical need in cancer care. The timing suggests confidence in both market conditions and clinical progress.